Company: BIVIW
Filing Date: 2025-08-08
Form Type: 424B5
Source: 0001520138-25-000247
Chunk: 40

Company: BIOVIE INC.
Filing Date: 2025-08-08
Form: 424B5
Chunk 40
---
 maintain, enforce and license any patents
that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify
patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, under certain of
our license or collaboration agreements, we may not have the right to control the preparation, filing, prosecution and maintenance of
patent applications, or to maintain the rights to patents licensed to or from third parties.

We currently are the assignee of a number of U.S.
provisional patent applications. U.S. provisional patent applications are not eligible to become issued patents until, among other things,
we file a non-provisional patent application within 12 months of filing one or more of our related provisional patent applications. With
regard to such U.S. provisional patent applications, if we do not timely file any non-provisional patent applications, we may lose our
priority dates with respect to our provisional patent applications and any patent protection on the inventions disclosed in our provisional
patent applications. Further, in the event that we do timely file non-provisional patent applications relating to our provisional patent
applications, we cannot predict whether any such patent applications will result in the issuance of patents or if such issued patents
will provide us with any competitive advantage.

<div align='center'>19</div>

As to our material inventions, trade secrets,
and intellectual property, our employees, consultants, and advisors execute confidentiality agreements and agree to disclose and assign
to us all inventions conceived during the workday, using our property, or which relate to our business. However, any of these parties
may breach these agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent
protection. Further, we may not be aware of all third-party intellectual property rights potentially relating to our drug candidates.
Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United
States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. Therefore, we cannot
know with certainty whether we were the first to make the inventions claimed in our patents or pending patent applications, or that we
were the first to file for patent protection of such inventions.

The patent position of pharmaceutical companies
generally is highly uncertain, involves complex legal, technological and factual questions and has, in recent years, been the subject